Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

@article{Wenzel2009AvosentanRA,
  title={Avosentan reduces albumin excretion in diabetics with macroalbuminuria.},
  author={Ren{\'e} R. Wenzel and Thomas Littke and Susan J Kuranoff and Christiane J{\"u}rgens and Heike Bruck and Eberhard Ritz and Thomas Philipp and Anna K Mitchell},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2009},
  volume={20 3},
  pages={655-64}
}
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is still a large need to improve the prevention and progression of diabetic nephropathy and its associated cardiovascular events. Endothelin antagonists have shown anti-inflammatory, antifibrotic, and antiproteinuric effects in experimental studies. This study was a randomized, placebo-controlled, double-blind, parallel-design, dosage-range study of the effect of the… CONTINUE READING